VKTX (Viking Therapeutics, Inc)
Insider Trading Activity
Every open-market purchase and sale reported by VKTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-07 | Dorothy Elizabeth Kelly-Gemmell | Director | A | — | — |
| 2026-08-07 | Dorothy Elizabeth Kelly-Gemmell | Director | A | — | — |
| 2026-07-29 | GREG ZANTE | Chief Financial Officer | MIXED | — | — |
| 2026-07-29 | Marianna Mancini | Chief Operating Officer | MIXED | — | — |
| 2026-07-29 | Brian Lian | President & CEO | MIXED | — | — |
| 2026-06-03 | Hubert C Chen | Chief Medical Officer | A | — | — |
| 2026-03-10 | Neil William Aubuchon | Chief Commercial Officer | Buy | — | — |
| 2026-01-26 | Neil William Aubuchon | Chief Commercial Officer | A | — | — |
| 2026-01-05 | Sarah Kathryn Rouan | Director | A | — | — |
| 2026-01-05 | MATTHEW W FOEHR | Director | MIXED | — | — |
| 2026-01-05 | Charles A Rowland Jr | Director | A | — | — |
| 2026-01-05 | LAWSON MACARTNEY | Director | A | — | — |
| 2026-01-05 | J MATTHEW SINGLETON | Director | A | — | — |
| 2026-01-05 | Brian Lian | President & CEO | MIXED | — | — |
| 2026-01-05 | Marianna Mancini | Chief Operating Officer | MIXED | — | — |
| 2026-01-05 | GREG ZANTE | Chief Financial Officer | MIXED | — | — |
| 2025-10-28 | GREG ZANTE | Chief Financial Officer | MIXED | — | — |
| 2025-10-28 | Brian Lian | President & CEO | MIXED | — | — |
| 2025-10-28 | Charles A Rowland Jr | Director | MIXED | — | — |
| 2025-10-28 | Marianna Mancini | Chief Operating Officer | MIXED | — | — |
| 2025-07-03 | Marianna Mancini | Chief Operating Officer | MIXED | — | — |
| 2025-07-03 | GREG ZANTE | Chief Financial Officer | MIXED | — | — |
| 2025-07-03 | Brian Lian | President & CEO | MIXED | — | — |
| 2025-04-14 | MATTHEW W FOEHR | Director | M | — | — |
| 2025-04-08 | Sarah Kathryn Rouan | Director | Buy | — | — |
| 2025-04-02 | Sarah Kathryn Rouan | Director | Buy | — | — |
| 2025-01-06 | Sarah Kathryn Rouan | Director | A | — | — |
| 2025-01-06 | MATTHEW W FOEHR | Director | A | — | — |
| 2025-01-06 | Charles A Rowland Jr | Director | A | — | — |
| 2025-01-06 | J MATTHEW SINGLETON | Director | A | — | — |
| 2025-01-06 | LAWSON MACARTNEY | Director | A | — | — |
| 2025-01-06 | GREG ZANTE | Chief Financial Officer | MIXED | — | — |
| 2025-01-06 | Marianna Mancini | Chief Operating Officer | MIXED | — | — |
| 2025-01-06 | Brian Lian | President & CEO | MIXED | — | — |
| 2024-11-08 | LAWSON MACARTNEY | Director | MIXED | — | — |
| 2024-10-28 | GREG ZANTE | Chief Financial Officer | MIXED | — | — |
| 2024-10-25 | J MATTHEW SINGLETON | Director | MIXED | — | — |
| 2024-10-25 | Sarah Kathryn Rouan | Director | MIXED | — | — |
| 2024-09-20 | Brian Lian | President & CEO | MIXED | — | — |
| 2024-09-20 | J MATTHEW SINGLETON | Director | MIXED | — | — |
| 2024-08-22 | J MATTHEW SINGLETON | Director | MIXED | — | — |
| 2024-08-22 | Brian Lian | President & CEO | MIXED | — | — |
| 2024-08-19 | J MATTHEW SINGLETON | Director | MIXED | — | — |
| 2024-08-19 | Brian Lian | President & CEO | MIXED | — | — |
| 2024-08-14 | J MATTHEW SINGLETON | Director | MIXED | — | — |
| 2024-07-31 | Marianna Mancini | Chief Operating Officer | MIXED | — | — |
| 2024-07-31 | Brian Lian | President & CEO | MIXED | — | — |
| 2024-07-31 | GREG ZANTE | Chief Financial Officer | MIXED | — | — |
| 2024-05-03 | GREG ZANTE | Chief Financial Officer | MIXED | — | — |
| 2024-05-02 | Marianna Mancini | Chief Operating Officer | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 4,780,964 | — |
| — | President & CEO | 2,720,958 | — |
| — | Chief Operating Officer | 685,392 | — |
| — | Chief Operating Officer | 422,760 | — |
| — | Chief Financial Officer | 233,421 | — |
| — | Director | 135,186 | — |
| — | Chief Medical Officer | 91,547 | — |
| — | Chief Financial Officer | 67,000 | — |
| — | Director | 51,115 | — |
| — | Director | 33,150 | — |
| — | Director | 12,650 | — |
| — | Director | 6,333 | — |
| — | Chief Commercial Officer | 4,475 | — |
| — | Director | 4,390 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VKTX quote page; the site-wide leaderboard is on the insider transactions hub.